Metformin-phytochemical combination therapy in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic potential
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multifactorial metabolic disorder characterized by excessive hepatic lipid accumulation, insulin resistance, oxidative stress, and chronic inflammation. Its pathogenesis spans interconnected metabolic, inflammatory, and fibrotic pathways, limiting the efficacy of single-target therapeutic approaches. Metformin (MET), a first-line antidiabetic agent, improves hepatic lipid metabolism primarily through AMPK activation and enhanced fatty acid oxidation; however, its therapeutic impact on inflammatory and redox pathways remains limited, and its use is frequently associated with gastrointestinal adverse effects. In this context, phytochemicals-diverse plant-derived bioactive compounds with pleiotropic metabolic and antioxidant properties-have emerged as promising adjuncts to MET to achieve broader pathway coverage. For the first time, this comprehensive review evaluates preclinical in vivo evidence on metformin-phytochemical combination therapy in in vivo models of MASLD, with a specific focus on its mechanistic and therapeutic advantages over monotherapy. A comprehensive literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar. Only original preclinical in vivo studies evaluating the combination of metformin with an isolated phytochemical in animal models of MASLD were included. Data were extracted on compound identity, dosing regimens, experimental models, and metabolic,…
How strong is the evidence?
Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.